Sign inJoin waitlistJoin the waitlist

Fadi Haddad

Assistant Professor · University of Texas M D Anderson Cancer Center

Credentials: · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2024–2027
Internal Medicine
2021–2024
Doctor of Medicine
2012–2016

Research

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial
The Lancet Haematology · 2023 · 226 citations
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute…
The Lancet Haematology · 2023 · 116 citations
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
Review · Journal of Hematology & Oncology · 2023 · 101 citations

Hagop Kantarjian
92 papers
Elias Jabbour
88 papers
Nicholas Short
72 papers
Nitin Jain
49 papers
Ghayas Issa
48 papers
KS
Koji Sasaki
48 papers
Tapan Kadia
47 papers
Guillermo Garcia-Manero
37 papers
Naval Daver
37 papers
Courtney DiNardo
34 papers
GB
Gautam Borthakur
34 papers
Jayastu Senapati
33 papers · 10 as a fellow

Clinical trials

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2029
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2027